Becton Dickinson at 13x Earnings: MedTech’s Most Mispriced Compounder

Becton Dickinson (BDX) trades at a 13x forward P/E multiple, representing a significant discount to medtech peers despite strong fundamentals including 60% U.S. infusion pump market share, 90%+ recurring revenue, and record 25% adjusted operating margins. The post-spin-off transition year narrative masks an emerging pure-play MedTech company with billion-dollar growth platforms in GLP-1 drug delivery and connected care, supported by $4 billion in fresh capital deployment and ongoing margin expansion targeting 26%+ territory.

05/07/2026, 4:14 AM • Investing

Robotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032

The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.

04/09/2026, 4:57 AM • GlobeNewswire

EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks

The Iran-Israel conflict and potential Strait of Hormuz disruption are creating supply chain pressures on medical supplies through petrochemical derivatives. Key inputs like naphtha and methanol used in pharmaceutical packaging and drug synthesis are experiencing price increases. While hospitals haven't yet felt the impact, analysts expect cost pressures on IV bags, tubing, and other critical consumables to surface within 2-4 weeks as the disruption ripples through supply chains.

03/25/2026, 8:01 AM • Benzinga

Manufacturing Disruption Hits Baxter Cancer Drug Supply In Europe

Baxter International faces a significant supply shortage of ifosfamide cancer drugs across the European Union due to a technical disruption at a third-party manufacturing facility. The company, the primary EU supplier, has implemented quota-based distribution and advised healthcare providers to prioritize existing patients. Supply constraints are expected to persist until Q1 2027. The shortage announcement coincided with Baxter's disappointing 2026 guidance, with adjusted EPS forecasted at $1.85-$2.05 versus consensus of $2.25.

03/24/2026, 1:24 PM • Benzinga

The ’Battleship’ Plan for 8.2%+ Dividends

The article recommends two closed-end funds (CEFs) for income-focused investors seeking high monthly dividends. BlackRock Enhanced Equity Dividend Trust (BDJ) offers an 8.2% yield with diversified holdings and is trading at a 6% discount to NAV. PIMCO Corporate & Income Opportunity Fund (PTY) provides an 11.5% yield and is positioned to benefit from declining interest rates, trading at a 6.5% premium to NAV that the author considers undervalued.

03/17/2026, 5:26 AM • Investing

Intravenous (IV) Solutions Market Size to Reach USD 29.47 Billion by 2035 Due to the Increasing Prevalence of Chronic Diseases Globally | SNS Insider

The global IV solutions market is projected to grow from USD 13.35 billion in 2025 to USD 29.47 billion by 2035, with a CAGR of 8.24%. Growth is driven by increasing prevalence of chronic diseases, rising hospital admissions, and growing demand for parenteral nutrition and critical care solutions. The U.S. market alone is expected to reach USD 8.39 billion by 2035. North America leads with 40.70% market share, while Asia-Pacific shows the fastest growth at 9.46% CAGR.

03/13/2026, 4:30 AM • GlobeNewswire

[Latest] Global Intravenous Infusion Pump Market Size/Share Worth USD 14.02 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global intravenous infusion pump market was valued at USD 6.72 billion in 2025 and is projected to reach USD 14.02 billion by 2035, growing at a CAGR of 7.6%. Growth is driven by increasing chronic diseases, aging populations, technological advancements in smart pumps, and rising demand for precise medication delivery in hospitals and home care settings.

03/09/2026, 6:30 PM • GlobeNewswire

Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS Insider

The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.

02/19/2026, 6:00 AM • GlobeNewswire

Hemostasis Products Market Size to Reach USD 3.28 Billion by 2035 with 5.41% CAGR – SNS Insider

The global hemostasis products market is projected to grow from USD 1.94 billion in 2025 to USD 3.28 billion by 2035, at a CAGR of 5.41%. Growth is driven by increasing surgical procedures, trauma cases, and demand for advanced bleeding control technologies. However, high product costs and low reimbursement in developing nations pose challenges. Topical hemostats and sponge/pad forms dominate the market, while flowable hemostats and matrix/gel forms show fastest growth. North America leads with 41.62% market share, while Asia-Pacific is the fastest-growing region.

02/17/2026, 8:00 AM • GlobeNewswire

Global Fibrin Sealant Market Size to Reach USD 3.57 Billion by 2035 with 8.37% CAGR – SNS Insider

The global fibrin sealant market is projected to grow from USD 1.60 billion in 2025 to USD 3.57 billion by 2035 at a CAGR of 8.37%, driven by increasing surgical volumes, minimally invasive procedures, and expanding applications in trauma and wound care. However, high costs and insurance coverage limitations remain barriers to adoption in emerging markets.

02/17/2026, 3:51 AM • GlobeNewswire

Why Baxter International Stock Was Tumbling Today

Baxter International's stock fell 15.58% after the company reported mixed Q4 2025 earnings with a revenue beat but significant earnings miss. While sales rose 8% to $2.97 billion, non-GAAP net income dropped 24% to $0.44 per share, falling short of analyst expectations of $0.54 per share. The company's 2026 guidance forecasting flat to 1% sales growth and lower adjusted earnings per share ($1.85-$2.05 vs. $2.27 in 2025) further disappointed investors.

02/12/2026, 2:10 PM • The Motley Fool

Baxter Shares Tank As 2026 Profit Guidance Falls Below Expectations

Baxter International reported fourth-quarter adjusted EPS of 44 cents, missing guidance of 52-57 cents and Wall Street estimates of 54 cents, primarily due to unfavorable product mix. While sales of $2.974 billion beat consensus expectations with 8% year-over-year growth, the company issued weak 2026 guidance with adjusted earnings of $1.85-$2.05 per share versus consensus of $2.25. Baxter shares fell 15.6% to $18.79, trading near 52-week lows.

02/12/2026, 1:10 PM • Benzinga

Is Baxter International an Underrated Healthcare Investment Play?

Baxter International has cut its dividend significantly and faced a 75% stock decline over five years due to inconsistent revenue and negative earnings. However, the company's essential medical products, attractive valuation metrics, and strong demographic tailwinds from an aging population may appeal to turnaround and value investors, though recovery could be uneven and prolonged.

02/06/2026, 10:15 AM • The Motley Fool

[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global advanced wound closure market is projected to grow from USD 18.47 billion in 2025 to USD 32.54 billion by 2035, at a CAGR of 6.9%. Growth is driven by increasing surgical procedures, rising chronic wounds and diabetes cases, and technological innovations in surgical sealants, hemostats, and tissue adhesives. North America leads the market while Asia Pacific shows the highest growth potential.

02/02/2026, 2:30 PM • GlobeNewswire

Elastomeric Infusion Pumps Market worth $1.49 billion by 2030 at 5.3%, says MarketsandMarkets™

The elastomeric infusion pumps market is projected to grow from USD 1.15 billion in 2025 to USD 1.49 billion by 2030 at a CAGR of 5.3%. Growth is driven by increased demand for reliable drug delivery systems in home healthcare and ambulatory care, rising chronic disease prevalence, and advancements in product design. North America leads the market, with continuous-rate pumps dominating the segment.

01/29/2026, 9:00 AM • GlobeNewswire